A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT GlObal Study in Subjects With Heart Failure With Reduced EjectIon FrAction (VICTORIA)
Latest Information Update: 28 May 2024
At a glance
- Drugs Vericiguat (Primary)
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Acronyms VICTORIA
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 08 Apr 2024 Results assessing the vericiguat treatment effects in VICTORIA across the spectrum of baseline risk and within the subset of VICTORIA patients with similar baseline characteristics to those enrolled in PARADIGM-HF and DAPA-HF presented at the 73rd Annual Scientific Session of the American College of Cardiology
- 01 Sep 2023 Results assessing herence to guideline use of angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, angiotensin receptor-neprilysin inhibitors, beta-blockers, and mineralocorticoid receptor antagonists. published in the Circulation: Heart Failure
- 01 Sep 2023 Results published in the European Journal of Heart Failure